Open Access

MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease

  • Authors:
    • Manal S. Fawzy
    • Essam Al Ageeli
    • Saeed Awad Al‑Qahtani
    • Baraah T. Abu Alsel
    • Shahad W. Kattan
    • Walla Alelwani
    • Eman A. Toraih
  • View Affiliations

  • Published online on: November 22, 2021     https://doi.org/10.3892/etm.2021.10985
  • Article Number: 63
  • Copyright: © Fawzy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diabetic nephropathy (DN) is a major risk factor for end‑stage renal disease (ESRD). MicroRNAs (miRNAs/miRs) and their variants may be implicated in health and disease, including DN. The present study aimed to investigate the association of the miRNA‑499a gene (MIR499A) A/G seed region variant (rs3746444) with DN‑associated ESRD susceptibility in patients with diabetes mellitus, and to determine whether there was an association between the different genotypes and the patients' laboratory and clinical data. A case‑control pilot study was conducted on 180 adult patients with type 2 diabetes mellitus. A total of 90 patients with ESRD on regular hemodialysis were considered as the cases, and 90 age‑, sex‑ and ethnicity‑matched diabetic patients with normo‑albuminuria were considered as the controls. MIR499A genotyping was performed using a TaqMan Real‑Time allele discrimination assay. Results demonstrated that the MIR499A rs3746444*G variant conferred susceptibility to the development of ESRD under co‑dominant [(odds ratio (95% confidence interval): 2.49 (1.41‑3.89) and 2.41 (1.61‑6.68) for heterozygous and homozygous comparison, respectively], dominant [2.30 (1.18‑3.90)] and allelic [1.82 (1.17‑2.83)] models. Different genotypes of the specified variant did not exhibit significant associations with the clinic‑laboratory data of the studied patients or the circulating miR‑499a plasma levels. In conclusion, results of the present study suggested that MIR499A rs3746444 may be a susceptibility variant for DN‑associated ESRD in the study population. However, larger sample size studies with different ethnicities are warranted to verify these findings.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fawzy MS, Al Ageeli E, Al‑Qahtani SA, Abu Alsel BT, Kattan SW, Alelwani W and Toraih EA: MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease. Exp Ther Med 23: 63, 2022
APA
Fawzy, M.S., Al Ageeli, E., Al‑Qahtani, S.A., Abu Alsel, B.T., Kattan, S.W., Alelwani, W., & Toraih, E.A. (2022). MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease. Experimental and Therapeutic Medicine, 23, 63. https://doi.org/10.3892/etm.2021.10985
MLA
Fawzy, M. S., Al Ageeli, E., Al‑Qahtani, S. A., Abu Alsel, B. T., Kattan, S. W., Alelwani, W., Toraih, E. A."MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease". Experimental and Therapeutic Medicine 23.1 (2022): 63.
Chicago
Fawzy, M. S., Al Ageeli, E., Al‑Qahtani, S. A., Abu Alsel, B. T., Kattan, S. W., Alelwani, W., Toraih, E. A."MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease". Experimental and Therapeutic Medicine 23, no. 1 (2022): 63. https://doi.org/10.3892/etm.2021.10985